<DOC>
	<DOC>NCT01412658</DOC>
	<brief_summary>Background: A novel milk peptide has been shown in laboratory setting to have natural anti-cancer properties and extend lifespan and improve metabolism in animal models. The purpose of this study was 1.) to determine the safety dosage range and, 2.) to determine whether this novel milk peptide positively influence blood markers, metabolism and improve quality of life.</brief_summary>
	<brief_title>Clinical Safety of a Novel Milk Protein Peptide</brief_title>
	<detailed_description>The study was conducted as a randomized, double-blind, placebo-controlled clinical trial in a university research setting. Healthy volunteers were randomly assigned to ingest in a double-blind and randomized manner either a placebo or milk peptides. Outcome measures were assessed at 0, 3, and 6 weeks of supplementation.</detailed_description>
	<mesh_term>Glycerol</mesh_term>
	<criteria>Healthy subjects with body mass index between 2740. have any metabolic disorders including known electrolyte abnormalities, heart disease, arrhythmias, diabetes, thyroid disease or hypogonadism; a history of hypertension, hepatorenal, musculoskeletal, autoimmune, or neurologic disease; if they are taking thyroid, hyperlipidemic, hypoglycemic, antihypertensive, or androgenic medications; have milk allergies</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>